{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:43:31Z","timestamp":1762868611331,"version":"3.40.4"},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"34","license":[{"start":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T00:00:00Z","timestamp":1630022400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>It is well known that liposome-based delivery of cytotoxic chemotherapeutics has been proposed as a putative strategy to enhance drug tolerability and efficacy compared to the conventional chemotherapy. However, its potential effect on improving prognosis remains largely unknown. The current meta-analysis is to explore the prognosis of cancer patients undergoing liposomal doxorubicin-based chemotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A detailed review of English and Chinese literature was conducted up to March 21, 2020. We evaluate its possible correlations using hazard ratios (HRs) with 95% confidence intervals (CIs). The pooled data were calculated by STATA software and Review Manager 5.3 software.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Consequently, 26 studies including 7943 patients were satisfied in current analysis. There were no significant differences between liposomal and conventional chemotherapy in OS (HR\u200a=\u200a0.98, 95%CI: 0.93\u20131.04, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.544) and PFS (HR\u200a=\u200a1.00, 95%CI: 0.92\u20131.10, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.945). Likewise, subgroup-analysis regarding country, cancer type, and sample sizes also showed the similar results of the 2 paired groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Taken together, our finding has demonstrated that there was no association of undergoing liposomal doxorubicin-based chemotherapy with cancer prognosis. However, detailed and further studies are needed to confirm our conclusion.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000026690","type":"journal-article","created":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T17:05:48Z","timestamp":1630083948000},"page":"e26690","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["The prognosis of cancer patients undergoing liposomal doxorubicin-based chemotherapy"],"prefix":"10.1097","volume":"100","author":[{"given":"Kai-Ping","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Chao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,8,27]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"07","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1021\/ar200105p","article-title":"Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine","volume":"44","author":"Al-Jamal","year":"2011","journal-title":"Acc Chem Res"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1021\/ar200011r","article-title":"Nanomedicine for cancer: lipid-based nanostructures for drug delivery and monitoring","volume":"44","author":"Namiki","year":"2011","journal-title":"Acc Chem Res"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.breast.2009.05.004","article-title":"Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet)","volume":"18","author":"Leonard","year":"2009","journal-title":"Breast"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"01","DOI":"10.1248\/bpb.b16-00624","article-title":"Liposomal delivery systems: design optimization and current applications","volume":"40","author":"Abu Lila","year":"2017","journal-title":"Biol Pharm Bull"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1049\/iet-nbt.2017.0321","article-title":"Synthesis and characterisation of liposomal doxorubicin with loaded gold nanoparticles","volume":"12","author":"Karimi Zarchi","year":"2018","journal-title":"IET Nanobiotechnol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.micres.2009.11.006","article-title":"Limitations in doxorubicin production from Streptomyces peucetius","volume":"165","author":"Malla","year":"2010","journal-title":"Microbiol Res"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.drup.2016.10.003","article-title":"New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy","volume":"29","author":"Gabizon","year":"2016","journal-title":"Drug Resist Updat"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2165\/00003495-199700544-00006","article-title":"Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers","volume":"54","author":"Muggia","year":"1997","journal-title":"Drugs"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2165\/00003495-199700544-00007","article-title":"Safety aspects of pegylated liposomal doxorubicin in patients with cancer","volume":"54","author":"Alberts","year":"1997","journal-title":"Drugs"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.tig.2004.06.014","article-title":"Meta-analysis of genetic association studies","volume":"20","author":"Munafo","year":"2004","journal-title":"Trends Genet"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"R15-20250504","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"J Natl Cancer Inst"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/jnci\/81.2.107","article-title":"Publication bias and dissemination of clinical research","volume":"81","author":"Begg","year":"1989","journal-title":"J Natl Cancer Inst"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/S0959-8049(01)00050-8","article-title":"Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL\/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group","volume":"37","author":"Judson","year":"2001","journal-title":"Eur J Cancer"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1093\/annonc\/mdg287","article-title":"Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma","volume":"14","author":"Dimopoulos","year":"2003","journal-title":"Ann Oncol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O\u2019Brien","year":"2004","journal-title":"Ann Oncol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/cncr.21662","article-title":"Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a phase III multicenter randomized trial","volume":"106","author":"Rifkin","year":"2006","journal-title":"Cancer"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3324\/haematol.2010.027862","article-title":"A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study","volume":"96","author":"Hunault-Berger","year":"2011","journal-title":"Haematologica"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1200\/JCO.2001.19.5.1444","article-title":"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventionaldoxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer","volume":"19","author":"Batist","year":"2001","journal-title":"J Clin Oncol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cncr.10201","article-title":"Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma","volume":"94","author":"Harris","year":"2002","journal-title":"Cancer"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/j.1365-2141.2008.07400.x","article-title":"Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia","volume":"143","author":"Latagliata","year":"2008","journal-title":"Br J Haematol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.lungcan.2009.06.017","article-title":"Phase II study of liposomal cisplatin (Lipoplatin) plus gemcitabine versuscisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB\/IV) non-small cell lung cancer","volume":"68","author":"Mylonakis","year":"2010","journal-title":"Lung Cancer"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1093\/annonc\/mdq234","article-title":"Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial","volume":"21","author":"Stathopoulos","year":"2010","journal-title":"Ann Oncol"},{"key":"R27-20250504","first-page":"208","article-title":"A randomized trial of liposomal paclitaxel plus cisplatin as first-line therapy for advanced non-small cell lung cancer","volume":"15","author":"Yang","year":"2012","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1093\/annonc\/mdt002","article-title":"A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma","volume":"24","author":"Roy","year":"2013","journal-title":"Ann Oncol"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1200\/JCO.2010.33.8566","article-title":"Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial","volume":"29","author":"Pignata","year":"2011","journal-title":"J Clin Oncol"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"03","DOI":"10.1186\/1741-7015-8-3","article-title":"A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study","volume":"8","author":"Bafaloukos","year":"2010","journal-title":"BMC Med"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1200\/JCO.2011.36.9215","article-title":"Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer","volume":"30","author":"Kaye","year":"2012","journal-title":"J Clin Oncol"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ygyno.2007.08.075","article-title":"Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatinversus carboplatin in platinum-sensitive (PS) patients with recurrent epithelialovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200)","volume":"108","author":"Alberts","year":"2008","journal-title":"Gynecol Oncol"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","article-title":"Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sentitive ovarian cancer in late relapse","volume":"28","author":"Pujade-Lauraine","year":"2010","journal-title":"J Clin Oncol"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","article-title":"Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer","volume":"25","author":"Mutch","year":"2007","journal-title":"J Clin Oncol"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1200\/JCO.2011.38.8082","article-title":"Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer","volume":"30","author":"Colombo","year":"2012","journal-title":"J Clin Oncol"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.1200\/JCO.2008.20.5013","article-title":"Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study","volume":"27","author":"Sparano","year":"2009","journal-title":"J Clin Oncol"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1093\/annonc\/mdh393","article-title":"Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer","volume":"15","author":"Chan","year":"2004","journal-title":"Ann Oncol"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"3893","DOI":"10.1200\/JCO.2004.08.157","article-title":"Randomized phase III trial of pegylated liposomal doxorubicin versusvinorelbine or mitomycin C plus vinblastine in women with taxane-refractoryadvanced breast cancer","volume":"22","author":"Keller","year":"2004","journal-title":"J Clin Oncol"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/annonc\/mdt543","article-title":"Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer","volume":"25","author":"Baselga","year":"2014","journal-title":"Ann Oncol"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/annonc\/mdt588","article-title":"A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG","volume":"25","author":"Smorenburg","year":"2014","journal-title":"Ann Oncol"},{"key":"R42-20250504","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10549-016-4033-3","article-title":"A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study","volume":"161","author":"Harbeck","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"R43-20250504","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.2217\/nnm-2018-0114","article-title":"Targeted bioadhesive nanomedicine: an effective approach for synergistic drug delivery to cancers","volume":"13","author":"Viswanadh","year":"2018","journal-title":"Nanomedicine (Lond)"},{"key":"R44-20250504","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1081\/CNV-100103136","article-title":"Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy","volume":"19","author":"Gabizon","year":"2001","journal-title":"Cancer Invest"},{"key":"R45-20250504","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ijpharm.2018.10.013","article-title":"Enhanced uptake and improved anti-tumor efficacy of doxorubicin loaded fibrin gel with liposomal apatinib in colorectal cancer","volume":"552","author":"Hu","year":"2018","journal-title":"Int J Pharm"},{"key":"R46-20250504","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ijpharm.2018.09.047","article-title":"A study on the role of cholesterol and phosphatidylcholine in various features of liposomal doxorubicin: from liposomal preparation to therapy","volume":"551","author":"Farzaneh","year":"2018","journal-title":"Int J Pharm"},{"key":"R47-20250504","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00280-014-2514-9","article-title":"Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx\u00ae)","volume":"74","author":"Boers-Sonderen","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"R48-20250504","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/(SICI)1097-0142(19990701)86:1<72::AID-CNCR12>3.0.CO;2-1","article-title":"Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes","volume":"86","author":"Symon","year":"1999","journal-title":"Cancer"},{"key":"R49-20250504","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/00003495-199700544-00005","article-title":"Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours","volume":"54","author":"Gabizon","year":"1997","journal-title":"Drugs"},{"key":"R50-20250504","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/CAD.0000000000000239","article-title":"Nonpegylated liposomal doxorubicin: reduction in cardiotoxicity, although still severe alopecia","volume":"26","author":"van den Hurk","year":"2015","journal-title":"Anticancer Drugs"},{"key":"R51-20250504","first-page":"351","article-title":"Molecular mechanisms of cisplatin and its liposomally encapsulated form, Lipoplatin\u2122. Lipoplatin\u2122 as a chemotherapy and antiangiogenesis drug","volume":"5","author":"Boulikas","year":"2007","journal-title":"Cancer Ther"},{"key":"R52-20250504","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1002\/1097-0142(20010501)91:9<1826::AID-CNCR1203>3.0.CO;2-J","article-title":"Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity","volume":"91","author":"Hong","year":"2001","journal-title":"Cancer"},{"key":"R53-20250504","doi-asserted-by":"crossref","first-page":"01","DOI":"10.1016\/j.cellimm.2017.04.005","article-title":"Tumor promoting role of anti-tumor macrophages in tumor microenvironment","volume":"316","author":"Goswami","year":"2017","journal-title":"Cell Immunol"},{"key":"R54-20250504","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1634\/theoncologist.2013-0126","article-title":"The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials","volume":"18","author":"Gibson","year":"2013","journal-title":"Oncologist"},{"key":"R55-20250504","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.clbc.2016.06.001","article-title":"Biweekly pegylated liposomal doxorubicin (Caelyx) in heavily pretreated metastatic breast cancer: a phase 2 study","volume":"16","author":"Jehn","year":"2016","journal-title":"Clin Breast Cancer"},{"key":"R56-20250504","doi-asserted-by":"crossref","first-page":"9645294","DOI":"10.1155\/2020\/9645294","article-title":"Chemotherapy options beyond the first line in HER-negative metastatic breast cancer","volume":"2020","author":"Lorusso","year":"2020","journal-title":"J Oncol"},{"key":"R57-20250504","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10549-010-0860-9","article-title":"Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study","volume":"122","author":"Alba","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"R58-20250504","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ejca.2014.11.017","article-title":"Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial","volume":"51","author":"Mahner","year":"2015","journal-title":"Eur J Cancer"},{"key":"R59-20250504","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.1997.15.3.987","article-title":"Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation","volume":"15","author":"Muggia","year":"1997","journal-title":"J Clin Oncol"},{"key":"R60-20250504","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00280-007-0525-5","article-title":"An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin","volume":"61","author":"Gabizon","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"R61-20250504","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-2249.2011.04515.x","article-title":"Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment","volume":"167","author":"Allavena","year":"2012","journal-title":"Clin Exp Immunol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026690","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T05:37:53Z","timestamp":1746337073000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026690"}},"subtitle":["A systematic review and meta-analysis"],"short-title":[],"issued":{"date-parts":[[2021,8,27]]},"references-count":61,"journal-issue":{"issue":"34","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000026690","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2021,8,27]]},"assertion":[{"value":"2021-02-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}